Shu Min Chen

US Patent:

20050235042, Oct 20, 2005

Filed:

Apr 16, 2004

Appl. No.:

10/826109

Inventors:

Todd Rumaner - Livermore CA, US
Shu Chen - Fremont CA, US
Michael Mulqueen - San Ramon CA, US

International Classification:

G06F015/167

US Classification:

709216000

Abstract:

A method for a memory device utility program includes (1) detecting a memory device being coupled to a host device, (2) in response to said detecting, locating files on the memory device, (3) displaying a file transfer page comprising a file transfer button for transferring the files on the memory device to the host device, and (4) in response to a user selecting the transfer button, transferring the files on the memory device to the host device.

US Patent:

20220380300, Dec 1, 2022

Filed:

Jul 20, 2022

Appl. No.:

17/869116

Inventors:

- Valby, DK
Anette Graven Sams - Vaerlose, DK
Xiaofang Wang - Shanghai, CN
Debasis Das - Shanghai, CN
Jian Hong - Shanghai, CN
Shu Hui Chen - Calabasas CA, US

Assignee:

H. Lundbeck A/S - Valby

International Classification:

C07C 235/06
A61P 25/08
A61P 25/06
A61P 25/04
A61P 25/24
A61P 25/22
A61P 25/28
A61P 25/18
C07C 235/08
C07C 235/26

Abstract:

The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

US Patent:

20220280455, Sep 8, 2022

Filed:

Jul 30, 2020

Appl. No.:

17/631762

Inventors:

- Valby, DK
Mario Rottlãnder - Greve, DK
Xiaofang Wang - Shanghai, CN
Debasis Das - Shanghai, CN
Jian Hong - Shanghai, CN
Shu Hui Chen - Calabasas CA, US
Jesper Frank Bastlund - Valby, DK
Jelena Ivkovic - Valby, DK
Karina Krøjer Søby - Valby, DK
Morten Grupe Larsen - Valby, DK

Assignee:

H. Lundbeck A/S - Valby

International Classification:

A61K 31/165

Abstract:

The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

US Patent:

20210032196, Feb 4, 2021

Filed:

Jul 30, 2020

Appl. No.:

16/943872

Inventors:

- Valby, DK
Xiaofang Wang - Shanghai, CN
Debasis Das - Shanghai, CN
Jian Hong - Shanghai, CN
Shu Hui Chen - Calabasas CA, US
Anette Graven Sams - Vaerlose, DK
Krestian Larsen - Ringsted, DK

International Classification:

C07C 235/08
C07C 255/44

Abstract:

The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

US Patent:

20200172474, Jun 4, 2020

Filed:

Feb 4, 2020

Appl. No.:

16/781106

Inventors:

- Valby, DK
Anette Graven Sams - Vaerlose, DK
Xiaofang Wang - Shanghai, CN
Debasis Das - Shanghai, CN
Jian Hong - Shanghai, CN
Shu Hui Chen - Calabasas CA, US

International Classification:

C07C 235/06
A61P 25/18
A61P 25/28
A61P 25/22
A61P 25/24
A61P 25/04
A61P 25/06
A61P 25/08
C07C 235/26
C07C 235/08

Abstract:

The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

US Patent:

20190256456, Aug 22, 2019

Filed:

Feb 20, 2018

Appl. No.:

15/899843

Inventors:

- Valby, DK
Anette Graven Sams - Vaerlose, DK
Xiaofang Wang - Shanghai, CN
Debasis Das - Shanghai, CN
Jian Hong - Shanghai, CN
Shu Hui Chen - Calabasas CA, US

International Classification:

C07C 235/06
A61P 25/08
A61P 25/06
A61P 25/18
A61P 25/24
A61P 25/22
A61P 25/28
A61P 25/04

Abstract:

The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.